Assessment of hepatocyte growth factor in ovarian cancer mortality

Ellen L Goode, Georgia Chenevix-Trench, Lynn C. Hartmann, Brooke L. Fridley, Kimberly R. Kalli, Robert A. Vierkant, Melissa C. Larson, Kristin L. White, Gary Keeney, Trynda N. Oberg, Julie M Cunningham, Jonathan Beesley, Sharon E. Johnatty, Xiaoqing Chen, Katelyn E. Goodman, Sebastian M. Armasu, David N. Rider, Hugues Sicotte, Michele M. Schmidt, Elaine A. ElliottEstrid Høgdall, Susanne Krüger Kjær, Peter A. Fasching, Arif B. Ekici, Diether Lambrechts, Evelyn Despierre, Claus Høgdall, Lene Lundvall, Beth Y. Karlan, Jenny Gross, Robert Brown, Jeremy Chien, David J. Duggan, Ya Yu Tsai, Catherine M. Phelan, Linda E. Kelemen, Prema P. Peethambaram, Joellen M. Schildkraut, Vijayalakshmi Shridhar, Rebecca Sutphen, Fergus J Couch, Thomas A. Sellers

Research output: Contribution to journalArticle

30 Citations (Scopus)

Abstract

Background: Invasive ovarian cancer is a significant cause of gynecologic cancer mortality. Methods: We examined whether this mortality was associated with inherited variation in approximately 170 candidate genes/regions [993 single-nucleotide polymorphisms (SNPs)] in a multistage analysis based initially on 312 Mayo Clinic cases (172 deaths). Additional analyses used The Cancer Genome Atlas (TCGA; 127 cases, 62 deaths). For the most compelling gene, we immunostained Mayo Clinic tissue microarrays (TMA, 326 cases) and conducted consortium-based SNP replication analysis (2,560 cases, 1,046 deaths). Results: The strongest initial mortality association was in HGF (hepatocyte growth factor) at rs1800793 (HR = 1.7, 95% CI = 1.3-2.2, P = 2.0 × 10 -5) and with overall variation in HGF (gene-level test, P = 3.7 × 10 -4). Analysis of TCGA data revealed consistent associations [e.g., rs5745709 (r 2 = 0.96 \with rs1800793): TCGA HR = 2.4, CI = 1.4-4.1, P = 2.2 × 10 -3; Mayo Clinic + TCGA HR = 1.6, CI = 1.3-1.9, P = 7.0 × 10 -5] and suggested genotype correlation with reduced HGF mRNAlevels (P = 0.01). In Mayo Clinic TMAs, protein levels of HGF, its receptor MET (C-MET), and phospho-MET were not associated with genotype and did not serve as an intermediate phenotype; however, phospho-MET was associated with reduced mortality (P = 0.01) likely due to higher expression in early-stage disease. In eight additional ovarian cancer case series, HGF rs5745709 was not associated with mortality (HR = 1.0, CI = 0.9-1.1, P = 0.87). Conclusions: Weconclude that although HGF signaling is critical to migration, invasion, and apoptosis, it is unlikely that HGF genetic variation plays a major role in ovarian cancer mortality. Furthermore, any minor role is not related to genetically-determined expression. Impact: Our study shows the utility of multiple data types and multiple data sets in observational studies.

Original languageEnglish (US)
Pages (from-to)1638-1648
Number of pages11
JournalCancer Epidemiology Biomarkers and Prevention
Volume20
Issue number8
DOIs
StatePublished - Aug 2011

Fingerprint

Hepatocyte Growth Factor
Ovarian Neoplasms
Mortality
Single Nucleotide Polymorphism
Genotype
Proto-Oncogene Proteins c-met
Genes
Atlases
Observational Studies
Neoplasms
Genome
Apoptosis
Phenotype
Proteins

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Goode, E. L., Chenevix-Trench, G., Hartmann, L. C., Fridley, B. L., Kalli, K. R., Vierkant, R. A., ... Sellers, T. A. (2011). Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiology Biomarkers and Prevention, 20(8), 1638-1648. https://doi.org/10.1158/1055-9965.EPI-11-0455

Assessment of hepatocyte growth factor in ovarian cancer mortality. / Goode, Ellen L; Chenevix-Trench, Georgia; Hartmann, Lynn C.; Fridley, Brooke L.; Kalli, Kimberly R.; Vierkant, Robert A.; Larson, Melissa C.; White, Kristin L.; Keeney, Gary; Oberg, Trynda N.; Cunningham, Julie M; Beesley, Jonathan; Johnatty, Sharon E.; Chen, Xiaoqing; Goodman, Katelyn E.; Armasu, Sebastian M.; Rider, David N.; Sicotte, Hugues; Schmidt, Michele M.; Elliott, Elaine A.; Høgdall, Estrid; Kjær, Susanne Krüger; Fasching, Peter A.; Ekici, Arif B.; Lambrechts, Diether; Despierre, Evelyn; Høgdall, Claus; Lundvall, Lene; Karlan, Beth Y.; Gross, Jenny; Brown, Robert; Chien, Jeremy; Duggan, David J.; Tsai, Ya Yu; Phelan, Catherine M.; Kelemen, Linda E.; Peethambaram, Prema P.; Schildkraut, Joellen M.; Shridhar, Vijayalakshmi; Sutphen, Rebecca; Couch, Fergus J; Sellers, Thomas A.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 20, No. 8, 08.2011, p. 1638-1648.

Research output: Contribution to journalArticle

Goode, EL, Chenevix-Trench, G, Hartmann, LC, Fridley, BL, Kalli, KR, Vierkant, RA, Larson, MC, White, KL, Keeney, G, Oberg, TN, Cunningham, JM, Beesley, J, Johnatty, SE, Chen, X, Goodman, KE, Armasu, SM, Rider, DN, Sicotte, H, Schmidt, MM, Elliott, EA, Høgdall, E, Kjær, SK, Fasching, PA, Ekici, AB, Lambrechts, D, Despierre, E, Høgdall, C, Lundvall, L, Karlan, BY, Gross, J, Brown, R, Chien, J, Duggan, DJ, Tsai, YY, Phelan, CM, Kelemen, LE, Peethambaram, PP, Schildkraut, JM, Shridhar, V, Sutphen, R, Couch, FJ & Sellers, TA 2011, 'Assessment of hepatocyte growth factor in ovarian cancer mortality', Cancer Epidemiology Biomarkers and Prevention, vol. 20, no. 8, pp. 1638-1648. https://doi.org/10.1158/1055-9965.EPI-11-0455
Goode, Ellen L ; Chenevix-Trench, Georgia ; Hartmann, Lynn C. ; Fridley, Brooke L. ; Kalli, Kimberly R. ; Vierkant, Robert A. ; Larson, Melissa C. ; White, Kristin L. ; Keeney, Gary ; Oberg, Trynda N. ; Cunningham, Julie M ; Beesley, Jonathan ; Johnatty, Sharon E. ; Chen, Xiaoqing ; Goodman, Katelyn E. ; Armasu, Sebastian M. ; Rider, David N. ; Sicotte, Hugues ; Schmidt, Michele M. ; Elliott, Elaine A. ; Høgdall, Estrid ; Kjær, Susanne Krüger ; Fasching, Peter A. ; Ekici, Arif B. ; Lambrechts, Diether ; Despierre, Evelyn ; Høgdall, Claus ; Lundvall, Lene ; Karlan, Beth Y. ; Gross, Jenny ; Brown, Robert ; Chien, Jeremy ; Duggan, David J. ; Tsai, Ya Yu ; Phelan, Catherine M. ; Kelemen, Linda E. ; Peethambaram, Prema P. ; Schildkraut, Joellen M. ; Shridhar, Vijayalakshmi ; Sutphen, Rebecca ; Couch, Fergus J ; Sellers, Thomas A. / Assessment of hepatocyte growth factor in ovarian cancer mortality. In: Cancer Epidemiology Biomarkers and Prevention. 2011 ; Vol. 20, No. 8. pp. 1638-1648.
@article{1e5adda38c034d12a5545d1f85b33339,
title = "Assessment of hepatocyte growth factor in ovarian cancer mortality",
abstract = "Background: Invasive ovarian cancer is a significant cause of gynecologic cancer mortality. Methods: We examined whether this mortality was associated with inherited variation in approximately 170 candidate genes/regions [993 single-nucleotide polymorphisms (SNPs)] in a multistage analysis based initially on 312 Mayo Clinic cases (172 deaths). Additional analyses used The Cancer Genome Atlas (TCGA; 127 cases, 62 deaths). For the most compelling gene, we immunostained Mayo Clinic tissue microarrays (TMA, 326 cases) and conducted consortium-based SNP replication analysis (2,560 cases, 1,046 deaths). Results: The strongest initial mortality association was in HGF (hepatocyte growth factor) at rs1800793 (HR = 1.7, 95{\%} CI = 1.3-2.2, P = 2.0 × 10 -5) and with overall variation in HGF (gene-level test, P = 3.7 × 10 -4). Analysis of TCGA data revealed consistent associations [e.g., rs5745709 (r 2 = 0.96 \with rs1800793): TCGA HR = 2.4, CI = 1.4-4.1, P = 2.2 × 10 -3; Mayo Clinic + TCGA HR = 1.6, CI = 1.3-1.9, P = 7.0 × 10 -5] and suggested genotype correlation with reduced HGF mRNAlevels (P = 0.01). In Mayo Clinic TMAs, protein levels of HGF, its receptor MET (C-MET), and phospho-MET were not associated with genotype and did not serve as an intermediate phenotype; however, phospho-MET was associated with reduced mortality (P = 0.01) likely due to higher expression in early-stage disease. In eight additional ovarian cancer case series, HGF rs5745709 was not associated with mortality (HR = 1.0, CI = 0.9-1.1, P = 0.87). Conclusions: Weconclude that although HGF signaling is critical to migration, invasion, and apoptosis, it is unlikely that HGF genetic variation plays a major role in ovarian cancer mortality. Furthermore, any minor role is not related to genetically-determined expression. Impact: Our study shows the utility of multiple data types and multiple data sets in observational studies.",
author = "Goode, {Ellen L} and Georgia Chenevix-Trench and Hartmann, {Lynn C.} and Fridley, {Brooke L.} and Kalli, {Kimberly R.} and Vierkant, {Robert A.} and Larson, {Melissa C.} and White, {Kristin L.} and Gary Keeney and Oberg, {Trynda N.} and Cunningham, {Julie M} and Jonathan Beesley and Johnatty, {Sharon E.} and Xiaoqing Chen and Goodman, {Katelyn E.} and Armasu, {Sebastian M.} and Rider, {David N.} and Hugues Sicotte and Schmidt, {Michele M.} and Elliott, {Elaine A.} and Estrid H{\o}gdall and Kj{\ae}r, {Susanne Kr{\"u}ger} and Fasching, {Peter A.} and Ekici, {Arif B.} and Diether Lambrechts and Evelyn Despierre and Claus H{\o}gdall and Lene Lundvall and Karlan, {Beth Y.} and Jenny Gross and Robert Brown and Jeremy Chien and Duggan, {David J.} and Tsai, {Ya Yu} and Phelan, {Catherine M.} and Kelemen, {Linda E.} and Peethambaram, {Prema P.} and Schildkraut, {Joellen M.} and Vijayalakshmi Shridhar and Rebecca Sutphen and Couch, {Fergus J} and Sellers, {Thomas A.}",
year = "2011",
month = "8",
doi = "10.1158/1055-9965.EPI-11-0455",
language = "English (US)",
volume = "20",
pages = "1638--1648",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Assessment of hepatocyte growth factor in ovarian cancer mortality

AU - Goode, Ellen L

AU - Chenevix-Trench, Georgia

AU - Hartmann, Lynn C.

AU - Fridley, Brooke L.

AU - Kalli, Kimberly R.

AU - Vierkant, Robert A.

AU - Larson, Melissa C.

AU - White, Kristin L.

AU - Keeney, Gary

AU - Oberg, Trynda N.

AU - Cunningham, Julie M

AU - Beesley, Jonathan

AU - Johnatty, Sharon E.

AU - Chen, Xiaoqing

AU - Goodman, Katelyn E.

AU - Armasu, Sebastian M.

AU - Rider, David N.

AU - Sicotte, Hugues

AU - Schmidt, Michele M.

AU - Elliott, Elaine A.

AU - Høgdall, Estrid

AU - Kjær, Susanne Krüger

AU - Fasching, Peter A.

AU - Ekici, Arif B.

AU - Lambrechts, Diether

AU - Despierre, Evelyn

AU - Høgdall, Claus

AU - Lundvall, Lene

AU - Karlan, Beth Y.

AU - Gross, Jenny

AU - Brown, Robert

AU - Chien, Jeremy

AU - Duggan, David J.

AU - Tsai, Ya Yu

AU - Phelan, Catherine M.

AU - Kelemen, Linda E.

AU - Peethambaram, Prema P.

AU - Schildkraut, Joellen M.

AU - Shridhar, Vijayalakshmi

AU - Sutphen, Rebecca

AU - Couch, Fergus J

AU - Sellers, Thomas A.

PY - 2011/8

Y1 - 2011/8

N2 - Background: Invasive ovarian cancer is a significant cause of gynecologic cancer mortality. Methods: We examined whether this mortality was associated with inherited variation in approximately 170 candidate genes/regions [993 single-nucleotide polymorphisms (SNPs)] in a multistage analysis based initially on 312 Mayo Clinic cases (172 deaths). Additional analyses used The Cancer Genome Atlas (TCGA; 127 cases, 62 deaths). For the most compelling gene, we immunostained Mayo Clinic tissue microarrays (TMA, 326 cases) and conducted consortium-based SNP replication analysis (2,560 cases, 1,046 deaths). Results: The strongest initial mortality association was in HGF (hepatocyte growth factor) at rs1800793 (HR = 1.7, 95% CI = 1.3-2.2, P = 2.0 × 10 -5) and with overall variation in HGF (gene-level test, P = 3.7 × 10 -4). Analysis of TCGA data revealed consistent associations [e.g., rs5745709 (r 2 = 0.96 \with rs1800793): TCGA HR = 2.4, CI = 1.4-4.1, P = 2.2 × 10 -3; Mayo Clinic + TCGA HR = 1.6, CI = 1.3-1.9, P = 7.0 × 10 -5] and suggested genotype correlation with reduced HGF mRNAlevels (P = 0.01). In Mayo Clinic TMAs, protein levels of HGF, its receptor MET (C-MET), and phospho-MET were not associated with genotype and did not serve as an intermediate phenotype; however, phospho-MET was associated with reduced mortality (P = 0.01) likely due to higher expression in early-stage disease. In eight additional ovarian cancer case series, HGF rs5745709 was not associated with mortality (HR = 1.0, CI = 0.9-1.1, P = 0.87). Conclusions: Weconclude that although HGF signaling is critical to migration, invasion, and apoptosis, it is unlikely that HGF genetic variation plays a major role in ovarian cancer mortality. Furthermore, any minor role is not related to genetically-determined expression. Impact: Our study shows the utility of multiple data types and multiple data sets in observational studies.

AB - Background: Invasive ovarian cancer is a significant cause of gynecologic cancer mortality. Methods: We examined whether this mortality was associated with inherited variation in approximately 170 candidate genes/regions [993 single-nucleotide polymorphisms (SNPs)] in a multistage analysis based initially on 312 Mayo Clinic cases (172 deaths). Additional analyses used The Cancer Genome Atlas (TCGA; 127 cases, 62 deaths). For the most compelling gene, we immunostained Mayo Clinic tissue microarrays (TMA, 326 cases) and conducted consortium-based SNP replication analysis (2,560 cases, 1,046 deaths). Results: The strongest initial mortality association was in HGF (hepatocyte growth factor) at rs1800793 (HR = 1.7, 95% CI = 1.3-2.2, P = 2.0 × 10 -5) and with overall variation in HGF (gene-level test, P = 3.7 × 10 -4). Analysis of TCGA data revealed consistent associations [e.g., rs5745709 (r 2 = 0.96 \with rs1800793): TCGA HR = 2.4, CI = 1.4-4.1, P = 2.2 × 10 -3; Mayo Clinic + TCGA HR = 1.6, CI = 1.3-1.9, P = 7.0 × 10 -5] and suggested genotype correlation with reduced HGF mRNAlevels (P = 0.01). In Mayo Clinic TMAs, protein levels of HGF, its receptor MET (C-MET), and phospho-MET were not associated with genotype and did not serve as an intermediate phenotype; however, phospho-MET was associated with reduced mortality (P = 0.01) likely due to higher expression in early-stage disease. In eight additional ovarian cancer case series, HGF rs5745709 was not associated with mortality (HR = 1.0, CI = 0.9-1.1, P = 0.87). Conclusions: Weconclude that although HGF signaling is critical to migration, invasion, and apoptosis, it is unlikely that HGF genetic variation plays a major role in ovarian cancer mortality. Furthermore, any minor role is not related to genetically-determined expression. Impact: Our study shows the utility of multiple data types and multiple data sets in observational studies.

UR - http://www.scopus.com/inward/record.url?scp=79961231255&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79961231255&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-11-0455

DO - 10.1158/1055-9965.EPI-11-0455

M3 - Article

C2 - 21724856

AN - SCOPUS:79961231255

VL - 20

SP - 1638

EP - 1648

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 8

ER -